Wednesday, August 12, 2020

Did HHS Azar Just Usurp Trump On Corporate Parental Rights In International Gerrymandering Policy?

Why was Azar in Taiwan talking about a foreign national policy of another nation?

Was Azar granted any authority to speak on behalf of the United States?

I would love to see those memoranda because I find this behavior to be deeply disturbing.

DHHS's only authority when dealing with a foreign nation should be about CDC sub-recipient grant management, which should be about NIH and their tiny human lab rat activities.

Any such concerns could have been referred to the DHHS OIG to be referred out to DOJ to be referred out to the proper jurisdictions(s) to address any such issues with private research funded through public dollars.

What that has to do with shaping another nation's foreign policy, I have no idea, but we should ask Emperor Pence, because he has a long standing relationship with Eli Lilly and the Vice President is over foreign policy, where, the President is over domestic policies.

The Secretary of State has the signatory authority to sign off on any foreign policy engagements, but, hey, what do I know?

I know this looks like a usurpation of executive power.

I am quite sure there are those who are assigned to do real time field observations on this activity. 



But, just in case no will take the time out of their day to find out why Azar would be so brazenly bold to falsely advise Trump, while, from what I can see in a cursory glance, personally inure himself, in his official capacity of public office, to advocate for a foreign corporation, of which, he more than likely is still generating revenue, as a primary stakeholder of Eli Lilly, but, hey, what do I know?

I know Eli Lilly is in Taiwan and I bet Emperor Pence can tell us about his days when he was sending lots of emails back and forth to his friends, when he was in Indiana, that he does not want to let us read the contents, thereof.

Probably trafficking tiny humans stuff.


The Genetics and NeuroEndocrinology of Short Stature International Study (GeNeSIS) Consent For Data Collection: Core Program
Protocol Description
Theme logo
https://www.humatrope.com/
The main objective of this multicenter international study is the collection and analysis of data regarding safety and effectiveness of Humatrope® for the treatment of growth-hormone deficiency and other growth disorders. This study provides information to doctors prescribing growth hormone to treat children and adolescents, ultimately helping physicians to use these products more effectively.

The GeNeSIS study includes a core study and 5 sub-study modules: DNA Analysis, Growth Prediction, SHOX Deficiency, Neoplasia, and Idiopathic Short Stature. Objectives of the sub-studies are: to characterize gene defects associated with hypopituitarism, growth disorder or short stature; to develop accurate growth prediction models using clinical and biochemical data; to characterize the clinical, endocrine and other features associated with SHOX deficiency and related disorders; to characterize the natural history of neoplastic disease in children evaluated or treated for endocrine or growth disorders; and to examine the variability among genes, proteins and other biomarkers that may be related to growth in children in the United States who receive Humatrope for treatment of idiopathic short stature. (a.k.a. protein deficiencies).

Eligibility Criteria
Children of either sex who are being treated with Humatrope for growth failure are eligible to participate in the core study. Core study participants may also participate in applicable sub studies, through separate consents.
Boys: All ages
Girls: All ages

Growth failure is a fancy term for starving tiny humans whose parents have failed to provide for the best interests of the child (a.k.a. "The Poors" - always said with clinched teeth because there is never an issue when it comes to parental consent to use kids as lab rats when you own them through one of your corporate shape shifting NGOs.)

Requirements
Participation will only involve data collection and annual blood draws, starting during each participant’s first treatment with growth hormone and will continue during subsequent routine visits with the child’s doctor. The study will collect and record all medical record information from lab rat tests, x-rays and clinic visits.
Visits: None beyond normal clinical care
Duration: Until patient is no longer seen in clinic (a.k.a. "death.", but then again, we have all the identification data to continue billing to Medicaid for cost reimbursements).

Status: Open for Enrollment
Source(s) of Support
Eli Lilly and Company

Primary Investigator
Oscar Escobar, MD

Contact Information
To get started, please contact:
Ana Diaz, RN
412-692-6862
or
Virginia Stefanick, RN
412-692-7178


Move channel list right

Eli Lilly Basketball Clinic - Taipei, Taiwan

October 12, 2013 - On Saturday, The Pacers hosted a basketball clinic in conjunction with Eli Lilly. The purpose of the clinic was the promote healthy living among the youth of Taipei, Taiwan.

I also know one of Azar's primary platforms in DHHS is research and innovation, which means you need a vehicle to access your human lab rat populations, where, in this instance, is just so beautifully packaged for our viewing experience on the residuals of the peculiar institution, which is probably why Azar is doing what he is doing.

Always remember, corporations are people, too, with religious beliefs, who can adopt tiny humans, to provide parental consent for lab ratting.

#maytheheavensfall

Lilly Named One of America's Best Adoption-Friendly Workplaces



Voting is beautiful, be beautiful ~ vote.©

No comments: